Overview

Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic Fibrosis

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Previous work demonstrated that inhaled hypertonic saline (HS) reduces exacerbation frequency and improves lung function in adults with cystic fibrosis (CF). It is unclear, however, whether HS will benefit young patients suffering from CF. The investigators propose to further support the concept that HS can benefit children with mild CF lung disease by performing a relatively short, placebo controlled study of HS in 5-12 year olds, using lung function and mucociliary clearance as key outcome measures.
Phase:
N/A
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)